Works by Wernevik, Linda

Results: 9

A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 12, p. 1569, doi. 10.1002/psp4.12866

By:

Knöchel, Jane;
Nilsson, Catarina;
Carlsson, Björn;
Wernevik, Linda;
Hofherr, Alexis;
Gennemark, Peter;
Jansson‐Löfmark, Rasmus;
Isaksson, Rikard;
Rydén‐Bergsten, Tina;
Hamrén, Bengt;
Rekić, Dinko

Publication type:

Article

Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men.

Published in:

2006

By:

Wernevik, Linda C.;
Nyström, Per;
Johnsson, Gillis;
Nakanishi, Takashi;
Eriksson, Ulf G.;
Nyström, Per

Publication type:

journal article

Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran.

Published in:

2006

By:

Wernevik, Linda C.;
Nyström, Per;
Andersson, Magnus;
Johnsson, Gillis;
Bylock, Anders;
Nakanishi, Takashi;
Eriksson, Ulf G.;
Nyström, Per

Publication type:

journal article

An oral antisense oligonucleotide for PCSK9 inhibition.

Published in:

Science Translational Medicine, 2021, v. 13, n. 593, p. 1, doi. 10.1126/scitranslmed.abe9117

By:

Gennemark, Peter;
Walter, Katrin;
Clemmensen, Niclas;
Rekić, Dinko;
Nilsson, Catarina A.M.;
Knöchel, Jane;
Hölttä, Mikko;
Wernevik, Linda;
Rosengren, Birgitta;
Kakol-Palm, Dorota;
Wang, Yanfeng;
Yu, Rosie Z.;
Geary, Richard S.;
Riney, Stan J.;
Monia, Brett P.;
Isaksson, Rikard;
Jansson-Löfmark, Rasmus;
Rocha, Cristina S. J.;
Lindén, Daniel;
Hurt-Camejo, Eva

Publication type:

Article

Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.

Published in:

British Journal of Clinical Pharmacology, 2018, v. 84, n. 7, p. 1486, doi. 10.1111/bcp.13562

By:

Erlandsson, Fredrik;
Albayaty, Muna;
Chialda, Ligia;
Ericsson, Hans;
Amilon, Carl;
Nelander, Karin;
Jansson‐Löfmark, Rasmus;
Wernevik, Linda;
Kjaer, Magnus;
Bamberg, Krister;
Hartleib‐Geschwindner, Judith

Publication type:

Article

Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide.

Published in:

British Journal of Clinical Pharmacology, 2024, v. 90, n. 6, p. 1503, doi. 10.1111/bcp.16046

By:

Clewe, Oskar;
Rekić, Dinko;
Quartino, Angelica L.;
Carlsson, Björn;
Higashimori, Mitsuo;
Wernevik, Linda;
Hofherr, Alexis;
Rydén‐Bergsten, Tina;
Nilsson, Catarina;
Knöchel, Jane

Publication type:

Article

AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval.

Published in:

British Journal of Clinical Pharmacology, 2022, v. 88, n. 11, p. 4839, doi. 10.1111/bcp.15425

By:

Rekić, Dinko;
Azarov, Ivan;
Knöchel, Jane;
Sokolov, Victor;
Nilsson, Catarina;
Wernevik, Linda;
Han, David;
Rydén‐Bergsten, Tina;
Ebrahimi, Ahmad;
Dota, Corina;
Carlsson, Björn

Publication type:

Article

Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial.

Published in:

CTS: Clinical & Translational Science, 2022, v. 15, n. 10, p. 2493, doi. 10.1111/cts.13377

By:

Squire, Iain B.;
Gabrielsen, Anders;
Greasley, Peter J.;
Wernevik, Linda;
Hartleib‐Geschwindner, Judith;
Holden, Julie;
Johansson, Susanne;
Rudvik, Anna;
Sánchez, José;
Bamberg, Krister;
Melin, Johanna;
Whittaker, Andrew

Publication type:

Article

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study.

Published in:

CTS: Clinical & Translational Science, 2020, v. 13, n. 2, p. 275, doi. 10.1111/cts.12705

By:

Whittaker, Andrew;
Kragh, Åsa M.;
Hartleib‐Geschwindner, Judith;
Albayaty, Muna;
Backlund, Anna;
Greasley, Peter J.;
Heijer, Maria;
Kjaer, Magnus;
Forte, Pablo;
Unwin, Robert;
Wernevik, Linda;
Ericsson, Hans

Publication type:

Article